Biotechnology News & Press Release Distribution

Biotechnology

APAC
Global

ASTRI and Saint Francis University Sign MoU to Advance AI-Enabled Biomaterials and Digital Health Innovation

HONG KONG, Aug. 24, 2026 /PRNewswire/ -- The Hong Kong Applied Science and Technology Research Institute (ASTRI) and Saint Francis University (SFU) have signed a Memorandum of Understanding (MoU) to establish a strategic partnership focused on advancing research and development in AI-enabled biom...

2026-08-24 15:40 224

ASTRI and Saint Francis University Sign MoU to Advance AI-Enabled Biomaterials and Digital Health Innovation

ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"

* Development of Leptin receptor-based technology and hybrid LNP platform * Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential applications in CNS-targeted therapeutics * Technology validated by winning first place in...

2026-08-24 15:01 252

Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

* HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity * Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South...

2026-08-24 12:40 273

Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease

NEW YORK, Aug. 23, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug Administ...

2026-08-24 11:05 483

Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics

SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innov...

2026-08-24 09:54 380

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-08-24 09:00 764

Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

TAIPEI, Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of ...

2026-08-24 08:00 668

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year. During the reporting period, the company showcased strong organic growth momentum and sustainable earnings generation, with revenue reaching RMB 3.5882 billion, a 27.3% ...

2026-08-21 21:50 5596

CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed based o...

2026-08-21 20:08 4784

China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?

BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing renewed att...

2026-08-21 17:28 933

Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy

NANJING, China, Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Op...

2026-08-21 17:20 1175

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR) inhibitor ZE...

2026-08-21 16:03 1115

3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, representing a year-over-year growth of 3.9%. Net profit attributable to equity holders of the Company rea...

2026-08-21 15:39 3000

Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's Nat...

2026-08-21 13:30 1409

Sunshine Guojian Releases 2026 Interim Report:

Innovation-driven, Steady Advancement SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Sunshine Guojian", stock code: 688336.SH), a pioneer in China's antibody therapeutics, released its 2026 interim report. In the f...

2026-08-21 08:00 2993

Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026 Emerging Discovery Programs Build Momentum BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC Strong Cash Position Supports Continued Strategic Execution Conference Cal...

2026-08-21 07:10 2713

Angel Yeast's AHH Packaging Design Recognized with Red Dot Award

SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Angel Nutritech, a professional yeast biotechnology subsidiary underAngel Yeast (SSE: 600298), has been recognized for its Angel Human Health (AHH) yeast essence packaging design with a Red Dot Award: Brands & Communication Desig...

2026-08-21 00:06 2513

Angel Yeast's AHH Packaging Design Recognized with Red Dot Award

Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants

The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Shanghai Matwings Technology Co., Ltd. ("Matwings") today announced that GenSci148 Injection, an investigati...

2026-08-20 19:00 840

ISoOR 2026 Organoid Clinical Transformation Summit convened in Hangzhou

ICORE launched; nine companies joined as founding members HANGZHOU, China, Aug. 20, 2026 /PRNewswire/ -- On August 18, the International Society of Organoid Research (ISoOR) held its 2026 Organoid Clinical TransformationSummit in Hangzhou. Under the theme "From Biological Models to Credible Evid...

2026-08-20 13:08 960

ISoOR 2026 Organoid Clinical Transformation Summit convened in Hangzhou

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance[1]: Double-digit revenue growth and gross margin imp...

2026-08-20 08:02 2132

12 3 4 5 ... 353